获得性大疱性表皮松解症基底膜自身抗体靶抗原的定位研究

目的 探讨获得性大疱性表皮松解症(EBA)基底膜带自身抗体(BMZ—Ab)的靶抗原及其定位情况。方法 用免疫印迹(IB)、盐裂皮肤间接免疫荧光(IIF)、间接免疫电镜(IIEM)等方法检测6例EBA血清中。IgG型及IgA型BMZ—Ab识别的真表皮抗原以及抗原定位情况。结果 6例EBA血清中IgG型BMZ—Ab均结合真皮提取物中290ku蛋白，3例同时伴有结合290ku蛋白的IgA型BMZ—Ab。盐裂皮肤IIF显示BMZ真皮侧IgG线状沉积，IIEM示金颗粒沉积于BMZ致密下层，即真皮锚原纤维的Ⅶ型胶原处。结论 位于BMZ致密下层的Ⅶ型胶原是EBA中BMZ-Ab的特异性靶抗原，Ⅶ型胶原上的抗原表位可被EBA血清中IgG及IgA型BMZ—Ab识别。     

早期糖尿病视网膜病变药物治疗的药物经济学分析

目的：探讨不同方案治疗早期糖尿病视网膜病变的经济效果,找出既经济又有效的方案。方法：对目前临床常用的4种不同治疗方案（导升明、胰激肽原酶、复方血栓通胶囊、复方丹参滴丸,治疗时间均为90d）运用药物经济学方法进行成本-效果分析。结果：4种方案所需费用分别为1417.50元、810.00元、891.00元、656.10元;治疗有效率分别为94.25%、85.09%、85.17%、83.53%;成本-效果比分别为15.04、9.52、10.46、7.85。结论：复方丹参滴丸治疗效果较好,不良反应少,成本低廉。     

结节性甲状腺肿合并其他甲状腺疾病临床分析

目的探讨结节性甲状腺肿合并其他甲状腺疾病的临床特点。方法回顾性分析我院手术治疗的4622例结节性甲状腺肿中并存其他甲状腺疾病的临床资料。结果4622例结节性甲状腺肿中700例合并其他甲状腺疾病，1418例存在不同的诊断失误。结论在诊断结节性甲状腺肿的同时应注意其合并的其他甲状腺疾病。     

PCR-RSSO基础上HLA-Ⅰ、Ⅱ基因分型的研究

目的通过对PCR-DNA技术的分析,探讨人类白细胞抗原(HLA)基因分型方法。方法采用PCR反向序列特异性寡核苷酸(polymerase chain reaction-reverse sequence specific oligonucleotide,PCR-RSSO)杂交技术,建立改良半量扩增体系全自动HLA-I、Ⅱ等位基因分型方法,进行了635份血液标本HLA-A、B、C、DR、DQ等位基因分型,其中166份DNA同时采用序列特异性引物技术(PCR-SSP)和手工全量扩增体系PCR-RSSO技术。对全自动半量PCR-RSSO、PCR-SSP、手工PCR-RSSO 3种方法做两两比较。结果全自动半量PCR-RSSO的分型成功率为98.4%(3 124/3 175),PCR-SSP为98.8%(656/664),手工PCR-RSSO为88.3%(733/830)。经χ2检验,全自动半量PCR-RSSO与PCR-SSP的分型成功率无统计学差异,与手工PCR-RSSO有显著差异(P<0.05)。结论PCR-RSSO可识别HLA-Ⅰ,Ⅱ共706个等位基因,覆盖WHO命名委员会2000年公布的936个等位基因的75.43%;对706个HLA等位基因的分型均为中~高分辨率,有分辨纯合子等位基因的能力;易长期保存书面的实验原始资料,即杂交条;具有成本低、劳动强度低、省时和DNA消耗量少等优点。PCR-RSSO适合于造血干细胞移植和建立造血干细胞及脐带血干细胞库的组织配型。     

One‐ and two‐stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint

Phase II clinical trials are performed to investigate whether a novel treatment shows sufficient promise of efficacy to justify its evaluation in a subsequent definitive phase III trial, and they are often also used to select the dose to take forward. In this paper we discuss different design proposals for a phase II trial in which three active treatment doses and a placebo control are to be compared in terms of a single‐ordered categorical endpoint. The sample size requirements for one‐stage and two‐stage designs are derived, based on an approach similar to that of Dunnett. Detailed computations are prepared for an illustrative example concerning a study in stroke. Allowance for early stopping for futility is made. Simulations are used to verify that the specified type I error and power requirements are valid, despite certain approximations used in the derivation of sample size. The advantages and disadvantages of the different designs are discussed, and the scope for extending the approach to different forms of endpoint is considered. Copyright © 2008 John Wiley & Sons, Ltd.     

Measurement in clinical trials: A neglected issue for statisticians?

Biostatisticians have frequently uncritically accepted the measurements provided by their medical colleagues engaged in clinical research. Such measures often involve considerable loss of information. Particularly, unfortunate is the widespread use of the so‐called ‘responder analysis’, which may involve not only a loss of information through dichotomization, but also extravagant and unjustified causal inference regarding individual treatment effects at the patient level, and, increasingly, the use of the so‐called number needed to treat scale of measurement. Other problems involve inefficient use of baseline measurements, the use of covariates measured after the start of treatment, the interpretation of titrations and composite response measures. Many of these bad practices are becoming enshrined in the regulatory guidance to the pharmaceutical industry. We consider the losses involved in inappropriate measures and suggest that statisticians should pay more attention to this aspect of their work. Copyright © 2009 John Wiley & Sons, Ltd.     

Is the political system really related to health?

We analyze whether the political system and its stability are related to cross-country differences in health. We apply factor analysis on various national health indicators for a large sample of countries over the period 2000–2005 and use the outcomes of the factor analysis to construct two new health measures, i.e., the health of individuals and the quality of the health care sector. Using a cross-country structural equation model with various economic and demographic control variables, we examine the relationship between the type of regime and political stability on the one hand and health on the other. The political variables and the control variables are measured as averages over the period 1980–1999. Our results suggest that democracy has a positive relationship with the health of individuals, while regime instability has a negative relationship with the health of individuals. Government instability is negatively related to individual health via its link with the quality of the health care sector, while democracy is positively related with individual health through its link with income. Our main findings are confirmed by the results of a panel model and various sensitivity tests.     

间日疟原虫深圳株红内期SSUrDNA基因片段的克隆与序列分析

目的 体外扩增间日疟原虫深圳株红内期小亚单位核糖体核糖核酸编码基因(SSUrDNA)片段，研究其结构与功能。方法 设计一对特异性引物，采用聚合酶链反应(PCR)从间日疟原虫患者血样中扩增出间日疟原虫SSUrDNA片段，以PUC19质粒T载体构建重组子导入大肠杆菌JM109；阳性克隆双酶切鉴定后，双脱氧末端终止法测定序列。结果 间日疟原虫SSUrDNA扩增片段大小为341bp；阳性克隆双酶切及PCR扩增均得到预期大小的片段；序列测定插入片段为341bp，与Sal I株顺序相比，仅在第151位处缺失一个碱基C。结论 成功克隆了间日疟原虫SSUrDNA片段．该序列在间日疟原虫虫株间高度保守。     

国产促动力药物治疗功能性消化不良的成本-效果分析

目的　评价不同药物治疗功能性消化不良的经济效果。方法　运用经济学中的成本 -效果分析方法 ,对莫沙必利、伊托必利和吗丁啉治疗功能性消化不良方案进行分析。结果　莫沙必利与吗丁啉成本效果比相当 ,但所需增长的成本效果比高 ;伊托必利的成本效果比和增长的成本效果比均高于吗丁啉。结论　吗丁啉是治疗功能性消化不良的最佳用药方案     

改良泪道探通术治疗新生儿泪囊炎

新牛儿泪囊是婴幼儿常见病，作者应用自制的泪道探通冲洗针对28例新生儿泪囊炎进行了泪道探通冲洗治疗观察．疗效满意．报告如下。